These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2772867)

  • 41. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
    Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
    Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
    Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
    J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
    Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
    Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
    Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost.
    Peters RF; Lees CM; Mitchell KA; Tweed MF; Talbot MD; Wallis RB
    Thromb Haemost; 1991 Mar; 65(3):268-74. PubMed ID: 1710836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison between the use of recombinant hirudin and heparin during hemodialysis.
    van Wyk V; Badenhorst PN; Luus HG; Kotzé HF
    Kidney Int; 1995 Oct; 48(4):1338-43. PubMed ID: 8569097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of recombinant hirudin and standard heparin in the Wessler model.
    Bara L; Bloch MF; Samama MM
    Thromb Res; 1992 Oct; 68(2):167-74. PubMed ID: 1475779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hirudin and hirudin fragments].
    Deschamps A; Samama M
    Ann Cardiol Angeiol (Paris); 1992 Oct; 41(8):A49-53. PubMed ID: 1298182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of recombinant desulphatohirudin on arterial thrombosis in rats.
    Talbot MD; Ambler J; Butler KD; Lees CM; Mitchell KA; Peters RF; Tweed MF; Wallis RB
    Haemostasis; 1991; 21 Suppl 1():73-9. PubMed ID: 1654294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W
    Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model.
    Takiguchi Y; Asai F; Wada K; Hayashi H; Nakashima M
    Br J Pharmacol; 1995 Dec; 116(7):3056-60. PubMed ID: 8680743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
    Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
    Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.